Scinai Immunotherapeutics Reports Q1 2025 Financial Results
Scinai Immunotherapeutics Reports Q1 2025 Financial Results
Key Takeaways (TLDR)
Scinai Immunotherapeutics reported $586K revenue in Q1 2025, up from zero, showcasing growth in its CDMO business.
Scinai focuses on developing nanosized VHH antibodies for inflammatory diseases and offers CDMO services to biotech firms.
Scinai's innovative therapies target unmet medical needs, contributing to better healthcare outcomes for patients worldwide.
Scinai's financial performance improvements reflect its commitment to cutting-edge research and development in the biopharmaceutical industry.
Why it Matters
This news matters as it highlights Scinai Immunotherapeutics' financial performance, showing revenue growth and reduced losses. Investors and stakeholders in the biopharmaceutical industry may find the company's expanding CDMO business and innovative pipeline of biological products of interest.
Summary
Scinai Immunotherapeutics (NASDAQ: SCNI) reported first quarter 2025 financial results, showing growth in revenue and a decrease in net loss compared to the previous year. The company's revenue reached $586K, up from zero in the prior-year period, as its CDMO business expanded. R&D expenses dropped to $1.3M, and the net loss improved to $1.6M from $2.2M in Q1 2024. Cash and equivalents totaled $1M at quarter-end, down from $2M a year earlier.
Scinai is a biopharmaceutical company with two key business units focusing on developing biological therapeutic products and providing CDMO services. The company's innovative pipeline includes nanosized VHH antibodies targeting diseases with unmet medical needs. For more information, visit the company's website at www.Scinai.com.
This news story relied on a press release distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Scinai Immunotherapeutics Reports Q1 2025 Financial Results.